Facial cellulitis: Difference between revisions

No edit summary
No edit summary
Line 1: Line 1:
==Background==
==Background==
*Superficial soft tissue infection of the face
*Superficial soft tissue infection of the face
*Risk factors include immunosuppression, diabetes, vascular injury (due to radiation or trauma), foreign bodies
*Most commonly caused by [[S. pyogenes]] and [[S. aureus]], including [[MRSA]]
*Most commonly caused by S. pyogenes and S. aureus, including MRSA
 
===Risk Factors===
*[[immunosuppression]]
*[[diabetes]]
*[[vascular injury]] (due to radiation or trauma)
*[[foreign bodies]]


==Clinical Features==
==Clinical Features==
Line 37: Line 42:
==Evaluation==
==Evaluation==
*Diagnosis is clinical
*Diagnosis is clinical
*Consider labs, blood cx if patient is immunocompromised, risk factors, renal dysfunction
*Consider labs, blood culture if patient is immunocompromised, risk factors, renal dysfunction
*Bedside US to identify abscess
*Bedside US to identify abscess
*CT can identify deep, extensive infection that involve soft tissues of neck or pharynx
*CT can identify deep, extensive infection that involve soft tissues of neck or pharynx
Line 51: Line 56:
==Disposition==
==Disposition==
*Most patients can be treated with oral antibiotics as outpatient
*Most patients can be treated with oral antibiotics as outpatient
*Consider admission for:
 
**systemic signs of sepsis
===Consider admission for:===
**antibiotic intolerance
*systemic signs of sepsis
**immunosuppression  
*antibiotic intolerance
**extensive areas of erythema or induration
*immunosuppression  
**foreign bodies that cannot be removed in ED
*extensive areas of erythema or induration
**failure of outpatient therapy
*foreign bodies that cannot be removed in ED
*failure of outpatient therapy


==See Also==
==See Also==

Revision as of 17:33, 27 September 2016

Background

Risk Factors

Clinical Features

  • Erythema, edema, warmth, pain
  • Can be associated with chronic illness, trauma, insect bites, allergen exposure, dental caries, radiation exposure
  • Consider severe illness or sepsis with systemic symptoms (fever, tachycardia, hypotension, AMS)

Differential Diagnosis

Infectious

Trauma

  • Soft tissue contusion
  • Burn

Inflammatory

Immunologic

Evaluation

  • Diagnosis is clinical
  • Consider labs, blood culture if patient is immunocompromised, risk factors, renal dysfunction
  • Bedside US to identify abscess
  • CT can identify deep, extensive infection that involve soft tissues of neck or pharynx

Management

  • Analgesics
  • Remove foreign bodies from affected area if possible
  • Abscesses should be drained

Antibiotics

Tailor antibiotics by regional antibiogram[1]

Outpatient

Coverage primarily for Strep

MRSA coverage only necessary if cellulitis associated with: purulence, penetrating trauma, known MRSA colonization, IV drug use, or SIRS[2]

  • 5 day treatment duration, unless symptoms do not improve within that timeframe[2]
    • Cephalexin 500mg PO q6hrs OR
      • Add TMP/SMX DS 1 tab PO BID[3] if MRSA is suspected
      • Most cases of non-purulent cellulitis are caused by Strep. In these cases, the addition of TMP/SMX has been demonstrated to offer no clinical benefit over cephalexin alone.[4]
    • Clindamycin 450mg PO TID covers both Strep and Staph
    • Tetracyclines (like Doxycycline) should be avoided in non-purulent cellulitis due to high rates of Strep resistance[5]

Inpatient

Saltwater related cellulitis

coverage extended for Vibrio vulnificus

Freshwater related cellulitis

coverage extended for Aeromonas sp

Disposition

  • Most patients can be treated with oral antibiotics as outpatient

Consider admission for:

  • systemic signs of sepsis
  • antibiotic intolerance
  • immunosuppression
  • extensive areas of erythema or induration
  • foreign bodies that cannot be removed in ED
  • failure of outpatient therapy

See Also

External Links

References

  1. Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52
  2. 2.0 2.1 Stevens D, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52
  3. Cadena J, et al. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 55.12 (2011): 5430-5432.
  4. Pallin D, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clinical infectious diseases 56.12 (2013): 1754-1762
  5. Traub, W and Leonhard, B. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 43.1 (1997):10-20.